Lattice radiotherapy followed by chemoimmunotherapy for sustained disease control in bulky centrally located left hilar lung squamous cell carcinoma: A case report

RATIONALE: Bulky centrally located, locally advanced non-small cell lung cancer often abuts critical thoracic structures, making both upfront surgery and conventional radiotherapy dose escalation challenging. Lattice radiotherapy (LRT) may achieve tumor debulking while limiting radiation exposure to surrounding organs at risk. PATIENT CONCERNS: A 70-year-old man presented with a recurrent cough, sputum production, and hemoptysis for 6 months. DIAGNOSES: Contrast-enhanced chest computed tomography revealed a 6.6 cm × 6.0 cm irregular left hilar mass with mediastinal invasion, encasement of the adjacent trachea and vessels, and an indistinct interface with the esophagus. Bronchoscopic biopsy confirmed squamous cell carcinoma of the lung. The programmed death-ligand 1 tumor proportion score was 18%. The final diagnosis was left hilar lung squamous cell carcinoma, cT4N1M0, stage IIIA. INTERVENTIONS: After multidisciplinary team discussion, the patient underwent LRT followed by sequential paclitaxel, carboplatin, and tislelizumab, and then maintenance tislelizumab monotherapy. OUTCOMES: After 3 treatment cycles, the maximum lesion diameter decreased from 6.6 cm to 4.4 cm, meeting the criteria for partial response according to Response Evaluation Criteria in Solid Tumors version 1.1. Cough and hemoptysis resolved, and the squamous cell carcinoma antigen level decreased from 11.5 to 3.9 ng/mL. At the last follow-up, 12 months after treatment initiation, the lesion remained stable without definite disease progression, and no grade 3 or higher treatment-related adverse events were observed. LESSONS: For selected patients with bulky, centrally located, locally advanced lung squamous cell carcinoma who are potentially resectable but at high surgical risk, LRT followed by chemoimmunotherapy may be a feasible individualized strategy. The role of conversion surgery should be determined by dynamic multidisciplinary risk-benefit assessment.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-13
DOI
https://doi.org/10.1097/md.0000000000051515
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lattice radiotherapy followed by chemoimmunotherapy for sustained disease control in bulky centrally located left hilar lung squamous cell carcinoma: A case report

Guangzeng Zhou, Xinyu Chen, Yan Gui, Chuanyu You et al.
3 links
Medicine
Lung Cancer Diagnosis and Treatment
article

Lattice radiotherapy followed by chemoimmunotherapy for sustained disease control in bulky centrally located left hilar lung squamous cell carcinoma: A case report

Guangzeng Zhou, Xinyu Chen, Yan Gui, Chuanyu You, J Chen, Tian Xu, Juncai Ye, Qilin Wang, Xueping Yang, Lu Cao
article en

Abstract

RATIONALE: Bulky centrally located, locally advanced non-small cell lung cancer often abuts critical thoracic structures, making both upfront surgery and conventional radiotherapy dose escalation challenging. Lattice radiotherapy (LRT) may achieve tumor debulking while limiting radiation exposure to surrounding organs at risk. PATIENT CONCERNS: A 70-year-old man presented with a recurrent cough, sputum production, and hemoptysis for 6 months. DIAGNOSES: Contrast-enhanced chest computed tomography revealed a 6.6 cm × 6.0 cm irregular left hilar mass with mediastinal invasion, encasement of the adjacent trachea and vessels, and an indistinct interface with the esophagus. Bronchoscopic biopsy confirmed squamous cell carcinoma of the lung. The programmed death-ligand 1 tumor proportion score was 18%. The final diagnosis was left hilar lung squamous cell carcinoma, cT4N1M0, stage IIIA. INTERVENTIONS: After multidisciplinary team discussion, the patient underwent LRT followed by sequential paclitaxel, carboplatin, and tislelizumab, and then maintenance tislelizumab monotherapy. OUTCOMES: After 3 treatment cycles, the maximum lesion diameter decreased from 6.6 cm to 4.4 cm, meeting the criteria for partial response according to Response Evaluation Criteria in Solid Tumors version 1.1. Cough and hemoptysis resolved, and the squamous cell carcinoma antigen level decreased from 11.5 to 3.9 ng/mL. At the last follow-up, 12 months after treatment initiation, the lesion remained stable without definite disease progression, and no grade 3 or higher treatment-related adverse events were observed. LESSONS: For selected patients with bulky, centrally located, locally advanced lung squamous cell carcinoma who are potentially resectable but at high surgical risk, LRT followed by chemoimmunotherapy may be a feasible individualized strategy. The role of conversion surgery should be determined by dynamic multidisciplinary risk-benefit assessment.

MedicineVol. 105(46)
North Sichuan Medical University (CN), Affiliated Hospital of North Sichuan Medical College (CN)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon